CardioGLYX

CardioGLYX is a biotechnology company focused on developing novel therapies for cardiovascular diseases, with a specific emphasis on heart failure and cardiac fibrosis. The company's lead research centers on the inhibition of Galectin-3, a protein known to play a critical role in the development of tissue scarring and inflammation in the heart. By targeting the galectin pathway, CardioGLYX aims to provide disease-modifying treatments for patients with diastolic heart failure and other forms of cardiomyopathy where current options are limited. The company is currently in the pre-clinical stage, advancing its proprietary small molecule inhibitors toward regulatory filings.